|
|
Vaccine Detail
|
Allogenic Glioma Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: Allogenic Glioma Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007234
- Type: Inactivated or ""killed"" vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: Prominent tumor-associated antigens that others have considered suitable for vaccine development include tenascin (glioma-specific extracellular matrix), gp240 (chondroitin sulfate-associated antigen found in glioma), MAGE 1 and MAGE 3 (Hofman et al., 2010).
- Description: A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy. (NCIT_C2055).
This first-in-human study shows that the GBM6-AD/DC vaccine was well tolerated and was associated with an immune response in a subset of patients. No MTD was achieved in this trial. This small-scale pilot provides information for larger scale investigations into the use of this allogeneic vaccine source. (Olin et al., 2014)
|
| Host Response |
|
|
| References |
Hofman et al., 2010: Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anti-cancer agents in medicinal chemistry. 2010; 10(6); 462-470. [PubMed: 20879986].
NCIT_C2055: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2055]
Olin et al., 2014: Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. Journal for immunotherapy of cancer. 2014; 2; 4. [PubMed: 24829761].
|
|
